Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on systemic necrotizing vasculitis.

D L Conn1

  • 1Division of Rheumatology, Mayo Clinic, Rochester, MN 55905.

Mayo Clinic Proceedings
|May 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cigarette smoking, disease severity and autoantibody expression in African Americans with recent-onset rheumatoid arthritis.

Annals of the rheumatic diseases·2008
Same author

The use of low-dose prednisone in the management of rheumatoid arthritis.

Bulletin on the rheumatic diseases·2002
Same author

Resolved: Low-dose prednisone is indicated as a standard treatment in patients with rheumatoid arthritis.

Arthritis and rheumatism·2001
Same author

Approach to the patient with suspected vasculitis.

Bulletin on the rheumatic diseases·2000
Same author

Alternative treatments and rheumatic diseases.

Bulletin on the rheumatic diseases·1999
Same author

The allure of alternative therapies.

Bulletin on the rheumatic diseases·1999
Same journal

37-Year-Old Woman With Jaundice.

Mayo Clinic proceedings·2026
Same journal

34-Year-Old Woman With An Unidentified Overdose.

Mayo Clinic proceedings·2026
Same journal

Use of Bronchoscopic Cryobiopsy in Evaluating Interstitial Lung Disease: Radiologic Predictors of Diagnostic Yield and Safety.

Mayo Clinic proceedings·2026
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
Same journal

Chronic Kidney Disease-In the Limelight, July 2026.

Mayo Clinic proceedings·2026
See all related articles

Systemic necrotizing vasculitides are classified by clinical and pathological patterns. Management requires considering glucocorticoid effects on vasoconstriction and platelet aggregation for ischemic complications.

Area of Science:

  • Rheumatology
  • Pathology
  • Vascular Medicine

Background:

  • Systemic necrotizing vasculitides encompass a group of diseases characterized by inflammation and necrosis of blood vessels.
  • These conditions present with diverse clinical and laboratory abnormalities, necessitating precise classification.
  • Understanding the underlying pathophysiology is crucial for effective diagnosis and management.

Purpose of the Study:

  • To outline the classification of systemic necrotizing vasculitides based on clinical and pathological findings.
  • To highlight common clinical and laboratory features associated with these vasculitides.
  • To discuss the implications of vascular inflammation and treatment side effects on patient outcomes.

Main Methods:

  • Classification of vasculitic syndromes based on patterns of clinical and pathological involvement.

Related Experiment Videos

  • Diagnosis relies on clinical features, with vascular involvement confirmed by biopsy or angiography.
  • Evaluation of treatment effects, including glucocorticoids, on vascular physiology.

    • Main Results:

    • Systemic necrotizing vasculitides are categorized according to their clinical and pathological manifestations.
    • Common clinical and laboratory abnormalities are shared across different vasculitic syndromes.
    • The extent of visceral organ involvement significantly impacts patient prognosis.

    Conclusions:

    • Effective management of systemic necrotizing vasculitides necessitates a thorough understanding of disease classification and clinical presentation.
    • Glucocorticoids, while crucial for controlling inflammation, can exacerbate vasoconstriction and platelet aggregation.
    • Careful consideration of these effects is vital for managing ischemic complications and optimizing patient care.